Vicore Pharma Holding AB (publ) (FRA:6Y4)
Germany flag Germany · Delayed Price · Currency is EUR
1.134
-0.002 (-0.18%)
Last updated: Jan 28, 2026, 8:23 AM CET

Vicore Pharma Holding AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
8.5109.35----
Revenue Growth (YoY)
-91.84%-----
Gross Profit
8.5109.35----
Selling, General & Admin
62.8250.4444.637.5321.6124.99
Research & Development
358.91249.26276.29249.97271.81142.02
Operating Expenses
421.72299.71320.89287.49293.42167.01
Operating Income
-413.22-190.36-320.89-287.49-293.42-167.01
Interest Expense
-40.43-0.01-0-0.01-0.01-0.01
Interest & Investment Income
24.5321.0810.540.910.650.82
Currency Exchange Gain (Loss)
4.680.4-0.62-1.75-1.83-0.07
EBT Excluding Unusual Items
-424.45-168.89-310.97-288.34-294.61-166.27
Gain (Loss) on Sale of Investments
---0.36-0.47-2.121.41
Other Unusual Items
-----17.54
Pretax Income
-424.45-168.89-311.33-288.81-296.74-147.32
Income Tax Expense
--0.26-0.38-0.38-0.25-0.45
Net Income
-424.45-168.63-310.94-288.42-296.48-146.86
Net Income to Common
-424.45-168.63-310.94-288.42-296.48-146.86
Shares Outstanding (Basic)
22913797727054
Shares Outstanding (Diluted)
22913797727054
Shares Change (YoY)
104.85%41.72%33.71%3.64%28.44%26.04%
EPS (Basic)
-1.85-1.23-3.22-3.99-4.25-2.71
EPS (Diluted)
-1.85-1.23-3.22-3.99-4.25-2.71
Free Cash Flow
-344.13-164.95-249.58-299.92-265.17-119.94
Free Cash Flow Per Share
-1.50-1.21-2.58-4.15-3.81-2.21
Gross Margin
100.00%100.00%----
Operating Margin
-4860.85%-174.09%----
Profit Margin
-4992.90%-154.22%----
Free Cash Flow Margin
-4048.09%-150.85%----
EBITDA
-411.54-188.12-317.47-283.88-290.06-163.65
EBITDA Margin
--172.04%----
D&A For EBITDA
1.692.243.423.613.363.36
EBIT
-413.22-190.36-320.89-287.49-293.42-167.01
EBIT Margin
--174.09%----
Source: S&P Global Market Intelligence. Standard template. Financial Sources.